

From: Paul Gil  
To: Morris, Nevitt  
Cc: Bi, Lilia Lei  
Subject: RE: BLA 125610 CMC/ PMC Information Request 12.01.17  
Date: Sunday, December 03, 2017 1:59:37 PM  
Attachments: image002.png

(File Attachment comment)  
Hi Nevitt,  
I acknowledge receipt of this email.  
Thanks,  
Paul

From: Morris, Nevitt [mailto:Nevitt.Morris@fda.hhs.gov]  
Sent: Friday, December 1, 2017 9:51 PM  
To: Jim Wang <jim.wang@sparktx.com>; Paul Gil <Paul.gil@sparktx.com>  
Cc: Morris, Nevitt <Nevitt.Morris@fda.hhs.gov>; Bi, Lilia Lei <LiliaLei.Bi@fda.hhs.gov>  
Subject: BLA 125610 CMC/ PMC Information Request 12.01.17

Hi Jim and Paul:

Below is our proposed final wording for the CMC PMCs. If you agree to these PMCs as written, please copy and submit to the BLA. If you have any questions on the wording of the PMCs, please request a telecon to discuss with FDA on Dec. 4, 2017.

1.  
Spark Therapeutics, Inc. commits to provide the shipping validation study protocol for shipment of the Drug Product from the distributor to a clinical site (or to Spark Therapeutics, Inc.) by January 31, 2018. A final study report will be submitted as a "Postmarketing Commitment - Final Study Report" by June 30, 2018.

2.  
Spark Therapeutics, Inc. commits to complete the verification studies for the following assays:

a.

(b) (4)

█

█

b.

(b) (4) █ tests for particulate matter for the Drug Product and Diluent, performed by (b) (4) █.

A final study report will be submitted as a "Postmarketing Commitment - Final Study Report" by March 31, 2018.

3.

Spark Therapeutics, Inc. commits to perform an analysis of the lot release test

results obtained from all Drug Substance (DS) and Drug Product (DP) lots manufactured within the first (b) (4) following approval, and evaluate if the

acceptance criteria for LUXTURNA lot release tests (including the

(b) (4)

) continue to provide adequate quality control for DS and DP based on the new data obtained from those tests.

A final study report will be submitted as a "Postmarketing Commitment - Final

(Unsigned signature field (Click to sign)) Signature field is unsigned

Study Report" by March 31, 2020.

4.

Spark Therapeutics, Inc. commits to conduct stability studies on the HEK293

Master Cell Bank (MCB) used for drug substance manufacture. (b) (4)

[REDACTED], "Postmarketing Commitment - Final Study Report" by March 31, 2018.

5.

Spark Therapeutics, Inc. commits to qualify the (b) (4)

[REDACTED]. A

final

study report will be submitted as a "Postmarketing Commitment - Final Study

Report" by March 31, 2018.

Thanks and please acknowledge receipt of this email.

Nevitt

Nevitt Morris

Nevitt  
Morris,  
RN,  
BSN,  
BS  
Consumer  
Safety  
Officer  
Office  
of  
Tissues  
and  
Advanced  
Therapies  
Center  
for  
Biologics  
Evaluation  
and  
Research  
(CBER)

U.S.  
Food  
and  
Drug  
Administration  
Building  
71,  
Room

4207  
10903  
New  
Hampshire  
Avenue  
Silver  
Spring,  
MD 20993  
Phone: (240)  
402-8269  
Fax: (301)  
595-1303  
Nevitt.Morris@fda.hhs.gov

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS  
ADDRESSED  
AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND  
PROTECTED  
FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person  
authorized to deliver  
the document to the addressee, you are hereby notified that any review,  
disclosure,  
dissemination, copying, or other action based on the content of this  
communication is not  
authorized. If you have received this document in error, please  
immediately notify the sender  
immediately by e-mail or phone.

This e-mail transmission may contain confidential or legally privileged  
information that is  
intended only for the individual(s) or entity(ies) named in the e-mail  
address. If you are not the  
intended recipient or an agent responsible for delivering it to the  
intended recipient, you are  
hereby notified that any disclosure, copying, distribution, or reliance  
upon the contents of this

e-mail is strictly prohibited. If you have received this e-mail transmission in error, please notify the sender immediately, and then please delete the message from your system. notify the sender immediately, and then please delete the message from your system.

